#BPMC

Thiard News@F4F

@newsen.bsky.social

8 months ago

Halper Sadeh LLC Launches Shareholder Investigations into BPMC, SAGE, and SOL Halper Sadeh LLC is investigating Blueprint Medicines, Sage Therapeutics, and Emeren Group for potential legal violations affecting shareholders' rights and transactions.

Halper Sadeh LLC Launches Shareholder Investigations into BPMC, SAGE, and SOL #United_States #New_York #Halper_Sadeh #Sage #BPMC

Thiard News@F4F

@newsen.bsky.social

9 months ago

Halper Sadeh LLC's Investigative Efforts on Shareholder Rights Concerning BPMC, STRM, ATAI, and STR Halper Sadeh LLC is actively investigating several companies, including BPMC, STRM, ATAI, and STR, to protect shareholder interests and rights.

Halper Sadeh LLC's Investigative Efforts on Shareholder Rights Concerning BPMC, STRM, ATAI, and STR #USA #New_York #Halper_Sadeh #BPMC #STRM

StockTitan

@stocktitan.net

9 months ago

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Sanofi has agreed to acquire Blueprint Medicines for $129.00 per share in cash ($9.1B total), plus potential CVR payments worth up to $6 per share, bringing the total potential value to $9.5B. The acquisition centers on Blueprint's Ayvakit/Ayvakyt, the only approved medicine for advanced and indolent systemic mastocytosis (SM), a rare immunological disease. Ayvakit generated $479M in revenue in 2024 and showed 60% YoY growth in Q1 2025. The deal includes Blueprint's pipeline assets: elenestinib (Phase 2/3 for SM) and BLU-808 (early-stage KIT inhibitor). The transaction represents a 27% premium to Blueprint's closing price and is expected to close in Q3 2025. The acquisition will be immediately accretive to gross margin and accretive to business operating income and EPS after 2026.

#BPMC #SNY Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

www.stocktitan.net/news/BPMC/sanofi-to-acqu...

interlaced.tv

@interlaced.bsky.social

10 months ago

#analogvideo #analog #glitch #crttv #videoart #videosynthesis #lzx #lzxindustries #syntonie #bpmc #videoart #videoartist #glitch #glitchart #glitchartist #videoglitch #analogvideo #analogvibes #eurorackvideo #videosynth #videosynthesis #modularvideo #artandtechnology #videofeedback #visuals #vhs

StockTitan

@stocktitan.net

10 months ago

Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance Blueprint Medicines (BPMC) reported strong Q1 2025 financial results, with AYVAKIT net product revenues reaching $149.4M, representing 61% year-over-year growth. The company raised its 2025 AYVAKIT revenue guidance to $700-720M, up from previous estimates. Q1 performance included $129.4M in US sales and $20M ex-US. The company reported a modest net income of $0.5M, boosted by a $50M one-time gain from selling its IDRx investment to GSK. Blueprint maintains a strong cash position of $899.8M and initiated two clinical proof-of-concept studies for BLU-808, targeting allergic rhinoconjunctivitis and chronic urticaria. The company remains confident in reaching its goal of $2B in AYVAKIT revenue by 2030, driven by growing systemic mastocytosis market opportunities.

#BPMC Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

www.stocktitan.net/news/BPMC/blueprint-medi...

Placeholder

@visual-lies.bsky.social

1 year ago

#lzx #lzxindustries #syntonie #bpmc #videoart #videoartist #glitch #glitchart #glitchartist #videoglitch #analogvideo #analogvibes #psychedelic #trippy #eurorack #eurorackvideo #videosynth #videosynthesis #modularvideo #modernartists #techspressionists #artandtechnology #videofeedback #visuals

Placeholder

@visual-lies.bsky.social

1 year ago

#lzx #lzxindustries #syntonie #bpmc #videoart #videoartist #glitch #glitchart #glitchartist #videoglitch #analogvideo #analogvibes #psychedelic #trippy #eurorack #eurorackvideo #videosynth #videosynthesis #modularvideo #modernartists #techspressionists #artandtechnology #videofeedback #visuals

Placeholder

@visual-lies.bsky.social

1 year ago

#lzx #lzxindustries #syntonie #bpmc #videoart #videoartist #glitch #glitchart #glitchartist #videoglitch #analogvideo #analogvibes #psychedelic #trippy #eurorack #eurorackvideo #videosynth #videosynthesis #modularvideo #modernartists #techspressionists #artandtechnology #videofeedback #visuals

Placeholder

@visual-lies.bsky.social

1 year ago

#lzx #lzxindustries #syntonie #bpmc #videoart #videoartist #glitch #glitchart #glitchartist #videoglitch #analogvideo #analogvibes #psychedelic #trippy #eurorack #eurorackvideo #videosynth #videosynthesis #modularvideo #modernartists #techspressionists #artandtechnology #videofeedback #visuals

Placeholder

@visual-lies.bsky.social

1 year ago

#lzx #lzxindustries #syntonie #bpmc #videoart #videoartist #glitch #glitchart #glitchartist #videoglitch #analogvideo #analogvibes #psychedelic #trippy #eurorack #eurorackvideo #videosynth #videosynthesis #modularvideo #modernartists #techspressionists #artandtechnology #videofeedback #visuals

Placeholder

@visual-lies.bsky.social

1 year ago

#lzx #lzxindustries #syntonie #bpmc #videoart #videoartist #glitch #glitchart #glitchartist #videoglitch #analogvideo #analogvibes #psychedelic #trippy #eurorack #eurorackvideo #videosynth #videosynthesis #modularvideo #modernartists #techspressionists #artandtechnology #videofeedback #visuals

Placeholder

@visual-lies.bsky.social

1 year ago

#lzx #lzxindustries #syntonie #bpmc #videoart #videoartist #glitch #glitchart #glitchartist #videoglitch #analogvideo #analogvibes #psychedelic #trippy #eurorack #eurorackvideo #videosynth #videosynthesis #modularvideo #modernartists #techspressionists #artandtechnology #videofeedback #visuals

Placeholder

@visual-lies.bsky.social

1 year ago

#lzx #lzxindustries #syntonie #bpmc #videoart #videoartist #glitch #glitchart #glitchartist #videoglitch #analogvideo #analogvibes #psychedelic #trippy #eurorack #eurorackvideo #videosynth #videosynthesis #modularvideo #modernartists #techspressionists #artandtechnology #videofeedback #visuals

Placeholder

@visual-lies.bsky.social

1 year ago

#lzx #lzxindustries #syntonie #bpmc #videoart #videoartist #glitch #glitchart #glitchartist #videoglitch #analogvideo #analogvibes #psychedelic #trippy #eurorack #eurorackvideo #videosynth #videosynthesis #modularvideo #modernartists #techspressionists #artandtechnology #videofeedback #visuals

Placeholder

@visual-lies.bsky.social

1 year ago

#lzx #lzxindustries #syntonie #bpmc #videoart #videoartist #glitch #glitchart #glitchartist #videoglitch #analogvideo #analogvibes #psychedelic #trippy #eurorack #eurorackvideo #videosynth #videosynthesis #modularvideo #modernartists #techspressionists #artandtechnology #videofeedback #visuals

StockTitan

@stocktitan.net

1 year ago

AYVAKIT Shows 93% Response Rate After 3 Years: Blueprint's Mast Cell Therapy Portfolio Expands AYVAKIT demonstrates sustained 3-year benefits with 93% patient response in systemic mastocytosis, while new BLU-808 achieves >80% tryptase reduction in Phase 1 trials.

#BPMC Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress

www.stocktitan.net/news/BPMC/blueprint-medi...

StockTitan

@stocktitan.net

1 year ago

Earnings: Blueprint's AYVAKIT Sales Surge 135% to $479M, Sets Ambitious $2B Target by 2030 Blueprint Medicines delivers strong Q4 results with AYVAKIT revenue reaching $144.1M. Company raises 2025 guidance and updates peak revenue potential to $4B.

#BPMC Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results

www.stocktitan.net/news/BPMC/blueprint-medi...

StockTitan

@stocktitan.net

1 year ago

Blueprint Medicines Raises Peak Revenue Target to $4B, Reports Strong AYVAKIT Growth Blueprint Medicines updates systemic mastocytosis franchise outlook, projecting $4B peak revenue. AYVAKIT sales expected to hit $475-480M in 2024, with positive BLU-808 trial data.

#BPMC Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth

www.stocktitan.net/news/BPMC/blueprint-medi...

Market Wire News

@marketwirenews.com

1 year ago

News; ( NASDAQ: #BPMC ) Expected US Company Earnings on Wednesday, October 30th, 2024

#StockMarket #News

Market Wire News

@marketwirenews.com

1 year ago

Breaking News: ( NASDAQ: #BPMC ) Outperform Recommendation Issued On BPMC By Oppenheimer

#StockMarket #News